Boston Scientific (BSX) Secures $455 Million For A Next Generation Heart Pump

Blackstone Life Sciences and Boston Scientific have partnered to co-fund the development of the VITALYST heart pump, a miniature device for cardiogenic shock patients. The $455 million collaboration leverages Boston Scientific's expertise and Blackstone's investment capabilities. The VITALYST system aims to improve cardiac output and blood circulation in severe heart attack cases.

Boston Scientific (BSX) reported Q3 2026 organic sales growth of 1.5%, below guidance, due to a cybersecurity incident. Margins and earnings declined, prompting a cut in full-year outlook. Management expects 2027 to be the trough, with recovery in 2028. Q3 revenues were $5.14B, with adjusted earnings of 73 cents per share, down 3% YoY.

Boston Scientific (BSX) stock rose 5.6% on November 2, 2026, after announcing positive results from the SIMPLAAFY trial for its WATCHMAN heart device. The study showed that patients taking a single-drug regimen performed as well as those on two drugs, potentially simplifying post-procedure care. The company also reported a 7% decline in U.S. sales for WATCHMAN in fiscal Q3 2026.

Boston Scientific and Blackstone Life Sciences (BXLS) agreed to a $455m co-funding deal for the VITALYST heart pump program. The device aims to improve treatment for acute myocardial infarction cardiogenic shock. Blackstone praised Boston Scientific's cardiovascular expertise and the potential of VITALYST. Separately, Boston Scientific reported positive six-month data from the SIMPLAAFY trial for its WATCHMAN FLX Pro device.

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.

Blackstone Life Sciences (BXLS) and Boston Scientific (BSX) have agreed to a $455 million collaboration to co-fund the development of the VITALYST™ heart pump for treating cardiogenic shock. The VITALYST system is designed to improve cardiac output and blood flow in patients with acute myocardial infarction. BXLS, with $18 billion in assets, will support BSX's cardiovascular franchise in bringing this new technology to market.